Imugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%

MT Newswires Live

Nov 27

Imugene (ASX:IMU) partnered with biotechnology company JW Therapeutics (Shanghai) to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.

The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.

Imugene shares rose 3% in afternoon trade on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586829060"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586829060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586829060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586829060","market":"sh","top_or_hot":-1,"title":"Imugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> Imugene (ASX:IMU) partnered with biotechnology company JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.</p><p>The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.</p><p>Imugene shares rose 3% in afternoon trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-27 10:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imugene (ASX:IMU) partnered with biotechnology company JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.</p><p>The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.</p><p>Imugene shares rose 3% in afternoon trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMU.AU","symbol_name":"IMUGENE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2586829060","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586829060","pubTimestamp":1764211066,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imugene  partnered with biotechnology company JW Therapeutics  to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.Imugene shares rose 3% in afternoon trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMU.AU":"IMUGENE LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Imugene与中国生物技术公司合作，在难治性实体瘤中试验联合疗法；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMU.AU":1},"content_text":"Imugene (ASX:IMU) partnered with biotechnology company JW Therapeutics (Shanghai) to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.Imugene shares rose 3% in afternoon trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}